Y Combinator's Portfolio of 66 Healthcare Startups: Smart Hardware, Biotech, and Health Tech Dominate
Y Combinator (hereinafter referred to as YC) is the world’s leading startup accelerator, founded in 2005 by Silicon Valley’s entrepreneurial pioneer Paul Graham. In its early years, YC primarily focused on the hardware and software sectors of the technology industry. It began expanding into the healthcare sector in 2011, initially concentrating on companies involved in healthcare information technology, such as drchrono, an electronic health record (EHR) management platform. Starting in 2014, amid the broader rise of the healthcare industry, YC gradually extended its investments to include medical devices, biotechnology, and artificial intelligence companies.
PayPal co-founder Peter Thiel (right), who invested in SpaceX and Facebook, is the entrepreneur who best embodies the Silicon Valley spirit.
Public data shows that Y Combinator (YC) has invested in 1,200 companies. VCBeat (WeChat ID: vcbeat) has identified 66 healthcare-related enterprises in which YC explicitly participated as an investor. These companies span 13 sectors, including healthcare informatics, health insurance solutions, technology outsourcing services, medical imaging processing, medical devices, artificial intelligence, health management platforms, smart hardware, smart technology, biotechnology, non-profit organizations, physician tools, and pharmaceuticals. Some of these companies, such as Medigram, Habit Labs, and Weave, have ceased operations (and are therefore excluded from this inventory), while others have gradually emerged as industry unicorns, such as AnalyticsMD. Due to the length of the article, it will be published in two parts.
What sets YC apart is its role in connecting investors and entrepreneurs. Functioning like a boot camp, selected startups undergo intensive mentoring by YC partners over a three-month period. These mentors include Silicon Valley luminaries who epitomize the region’s entrepreneurial spirit, such as Facebook founder Mark Zuckerberg and PayPal founder Peter Thiel. Peter Thiel, who invested in SpaceX and Facebook, is a formidable figure from the famed “PayPal Mafia.” In this year’s U.S. presidential election, he broke sharply with his traditional affiliations by casting his vote for the controversial Donald Trump. Evidently, these “mavericks” apply unconventional criteria when evaluating the merits of companies.
Demo Day is a global event held annually, where selected startups pitch to venture capitalists from around the world. Each cohort features approximately 100+ projects (most recently, 105 companies). Qualified companies receive $120,000 in investment in exchange for a minority equity stake (7%) acquired by Y Combinator (YC). After Demo Day, YC continues to closely monitor its portfolio companies, providing technical, advisory, and even financial support.
34.Airo Health
Smart Wristbands for Detecting Blood Nutrients
Established in: 2013
Headquarters Location: Ontario, Canada
Investment Date: August 2015
Investment Amount: $120,000
Investment Round: Seed Round
A smart device company has produced the world’s first tracking wristband for automatic calorie intake measurement. Airo can automatically track the calories you consume. It uses a built-in spectrometer that employs light of different wavelengths to detect nutrients released into the bloodstream as they break down during and after your meals. In August 2016, it secured $120,000 in seed funding from Y Combinator.
35.Luminostics
Home Disease Monitoring Devices
Establishment Date: 2014
Headquarters Location: San Jose, California
Investment Date: August 2016
Investment Amount: USD 120,000
Investment Round: Seed Round
Luminostics offers an innovative technology for diagnosing chlamydia, a sexually transmitted infection. Users simply need to load blood, urine, or saliva into a cartridge and insert it into a smartphone-compatible detection device. Within 15 minutes, users can receive their health results. In August 2016, the company secured $120,000 in investment from Y Combinator.
Unlike traditional outpatient care, Luminostics enables at-home monitoring, offering convenience and high efficiency. This technology was part of a doctoral research project and is scheduled for clinical trials next year. Currently, it remains in the research and development phase.
36.Bellabeat
Wearable Device Manufacturers Targeting Mothers and Expectant Mothers
Established in: 2013
Headquarters: San Francisco
Investment Date: May 2014
Investment Amount: $4.5 million (co-investment)
Investment Round: Seed Round
Bellabeat was founded in March 2014 with the mission of developing wearable devices to help women more conveniently track their overall health. The company participated in Y Combinator’s Winter 2014 batch and, after completing two rounds of seed funding, raised a total of $4.52 million.
Currently, Bellabeat offers three products: the Bellabeat Leaf (available in Nature and Urban editions), the Bellabeat Shell, and the Bellabeat Balance (which is no longer under development). The Leaf is a smart necklace that tracks women’s menstrual cycles. With a trendy design, it can be worn as a necklace or pendant. Priced at $119 for the basic version, it monitors women’s activity levels, sleep quality, stress indices, and reproductive health. The Shell features built-in sensors that allow expectant parents to listen to fetal heartbeats. It can record and play back audio, as well as measure ambient temperature and humidity. The Balance is a smart scale that enables mothers to track their weight during pregnancy, provides scientifically grounded healthy weight data, and even assists new mothers with postpartum weight loss.
Unlike typical wearable products, Bellabeat primarily targets “moms or moms-to-be” rather than general fitness enthusiasts, a demographic often overlooked by many health-tracking devices. The product’s major retailers include Target, Best Buy, Bloomingdale’s, London’s largest department store John Lewis, the UK-based Selfridges, Apple Authorized Resellers (in the UK and Gulf Arab countries), and Orange (in France and the UK).
37. Standard Cyborg
3D-Printed Waterproof Prosthetic Limb
Established in: 2014
Headquarters Location: Los Angeles
Investment Date: December 2014
Investment Amount: $120,000
Investment Round: Seed Round
Standard Cyborg is a medical hardware provider, with its flagship product being 3D-printed waterproof prosthetics that enable individuals who have lost their legs to regain mobility using conventional prosthetic devices. In December 2014, it received $120,000 in investment from Y Combinator (YC).
By integrating with structural scanners and Design Studio software, the system enables a 30-second limb scan via an iPad app to generate a 3D cast model. The company offers prosthetic fabrication services or can transmit the model to other C-Fab facilities for production. Medical prostheses such as artificial limbs are traditionally handmade, resulting in prohibitively high costs. Standard Cyborg leverages 3D printing technology to produce waterproof prosthetic legs priced at only $800. The company plans to expand its portfolio to include a more diverse range of prosthetic devices.
38. Lully
Hardware Company for Improving Children's Sleep Quality
Established in: 2014
Headquarters Location: San Francisco
Investment Date: June 2015
Investment Amount: $2.1 million
Investment Round: Seed Round
Lully was founded by a Stanford University engineer and physician who spent several years researching pediatric sleep, with the aim of helping entire families achieve better rest at night. The Lully device is priced at $169 and comes with a companion iOS app. In June 2015, it secured $2.1 million in funding from Y Combinator. Lully offers a device that can be placed under the mattress, utilizing automated vibrational humming and other tested technologies to help children sleep through the night. To ensure the practicality of this technology, Lully conducted trials over 10,000 nights; the solution was found to prevent 80% of night terrors in children, with sales driven primarily by word-of-mouth among users.
39.isono Health
Breast Cancer Detector
Established in: 2015
Headquarters: San Francisco
Investment Time: November 2015
Investment Amount: $120,000
Investment Round: Seed Round
iSono Health aims to make breast screening more accessible for women by developing a device capable of automated, repeatable 3D ultrasound imaging via wearable technology. Free from radiation risks, the ultrasound scanner connects to a wearable device, enabling women to perform monthly at-home screenings and monitor changes in just two minutes. Intelligent software generates monthly comparative reports based on the collected data, offering real-time feedback and personalized solutions to facilitate early detection of breast cancer. In November 2015, the company secured $120,000 in seed funding from Y Combinator; since then, no further public financing records have been disclosed.
40. Eight
Core Business: Sleep Tracking Services
Establishment Date: 2014
Headquarters Location: New York
Investment Date: June 2016
Investment Amount: $6 million
Investment Round: Seed Round
Eight specializes in sleep tracking services. In June 2015, it secured $6 million in funding from 11 investors, including Y Combinator and StartX.
The product launched by the company can track users’ daily bedtime, sleep onset time, wake-up time, and rising time, as well as body movement, heart rate, respiratory rate, and total sleep duration during sleep. It can also detect environmental factors that affect sleep, such as indoor temperature, humidity, light intensity, noise levels, and local weather changes.
Notably user-friendly, this smart mattress features over ten temperature regulation modes. When users sleep with a partner, the temperature can be adjusted independently on either side of the bed, allowing each individual to select their optimal sleeping temperature for high-quality rest. Once these data are collected, the companion app analyzes them to provide a sleep quality score. Additionally, users receive insights into trends of sleep deprivation, their sleep depth, and other tracked temporal sleep metrics.
41. CrowdMed
Rapid and Precise Resolution of Medical Issues Online Using the “Crowdsourcing” Model
Date of Establishment: October 1, 2012
Headquarters Location: San Francisco
Investment Period: February 2013, September 2015
Investment Amount: $1.1 million, $765,000
Investment Round: Seed Round
CrowdMed was founded in 2012 and is headquartered in San Francisco. It was one of the 46 startups selected for Y Combinator’s Winter 2013 batch. To date, the company has raised over $3 million in funding, including four rounds of seed investment. Founder Jared Heyman is a serial entrepreneur who had established two other companies prior to founding CrowdMed.
CrowdMed provides customized, comprehensive medical services. The platform assembles a team of “medical detectives” online, typically comprising retired physicians, nurses, medical students, researchers, and individuals who have recovered from illnesses. Leveraging their professional expertise, these detectives provide patients with the information they need, thereby streamlining healthcare workflows and developing solutions for patients with chronic conditions or difficult-to-diagnose complex diseases. However, the recommendations provided by the website are advisory in nature and do not constitute formal medical diagnoses. Depending on the benefits included, three subscription tiers are offered: Basic ($99), Standard ($149), and Premium ($249).
Overall, CrowdMed adopts a model driven by technology and collective intelligence. Patients submit their medical cases and upload previous diagnoses, laboratory tests, and other examination results. CrowdMed employs a precise and scientific algorithm to assist its “medical detectives” in selecting cases that match their areas of expertise. Extensive communication then takes place between physicians and patients, as well as among physicians themselves, ultimately leading to diagnostic conclusions and treatment recommendations. The company holds two U.S. patents and has invested millions of dollars, along with substantial human resources and time, in developing its core technologies. Therefore, technology remains a central pillar of CrowdMed’s operations.
42.Multiply Labs
3D-Printed Capsule Nutritional Supplements
Established: 2016
Headquarters: San Francisco
Investment Date: August 2016
Investment Amount: $120,000
Investment Round: Seed Round
Multiply Labs is undoubtedly a company brimming with ingenuity. The company uses simple MakerBot Replicator 2 3D printers and HPC (hydroxypropyl cellulose)-based filaments to print hollow capsules, which can be customized with varying levels of nutrients, such as vitamins and minerals, according to consumer demands. In August 2016, it secured $120,000 in funding from Y Combinator.
It is particularly noteworthy that with this 3D-printing technology for pharmaceuticals, parameters such as the size and shape of the capsules can be adjusted. Since the walls of the compartmentalized sections are soluble, the release timing of the nutritional agents can be modulated. Looking ahead, Multiply Labs holds immense potential in the nutritional supplements market.
43. The Flex Company
Menstrual Hygiene Products for Women
Established: 2015
Headquarters: Venice, California
Investment Period: May 2016, August 2016
Investment Amount: $120,000, $1 million
Investment Round: All Seed Rounds
The market for female menstrual products is vast, with sanitary pads and tampons currently dominating the landscape. Flex’s innovative disc-shaped menstrual product is a latex-free, disposable item characterized by low allergenicity. Most importantly, it allows women to engage in sexual activity during menstruation without any risk of toxic shock syndrome.
The product complies with FDA requirements, priced at $20 per menstrual cycle, with more favorable rates for quarterly purchases. In May 2015, it secured a $120,000 investment from Y Combinator (YC), followed by a $1 million funding round in August from three investors, including YC and FundersClub.
44. Zenamins
Customized Vitamin Platform
Established: 2014
Headquarters Location: San Francisco
Investment Date: July 2014
Investment Amount: $120,000
Investment Round: Seed Round
Individuals who take vitamin supplements often forget to do so regularly. Zenamins addresses this industry pain point, fostering long-term user engagement. Founded in 2014, Zenamins secured $120,000 in funding from the renowned startup incubator Y Combinator in July. However, publicly available information suggests that its fundraising performance has been lackluster; apart from Y Combinator, no subsequent investors have come forward.
Unlike the traditional approach of purchasing a bottle of off-the-shelf vitamin supplements at a pharmacy, Zenamins’ business model is characterized by fostering long-term user stickiness. The dosage and usage habits of each customer are accurately stored in Zenamins’ database. Notably, Zenamins allows users to customize the ingredients within their vitamin capsules. The company’s database includes 50 different vitamin or mineral components, such as vitamins A through K, mineral elements like iron, calcium, and zinc, as well as other compounds such as glucosamine. For those who are uncertain about their choices, Zenamins provides guidelines to assist in the selection process.
Secondly, Zenamins will prepare personalized dispensers based on your daily intake, making it easy to access the correct dosage each time and helping you avoid uncertainty about whether you have already taken your vitamins. Finally, these custom-formulated vitamin packs will be delivered directly to your home every four weeks. Of course, if you need a larger supply for an extended trip, simply notify Zenamins, and they will make the necessary arrangements for you.
45. Nightingale
Intelligent Medication Reminder
Establishment Date: July 2013
Headquarters Location: San Francisco
Investment Date: July 2014
Investment Amount: $120,000
Investment Round: Seed Round
Nightingale is a mobile app that helps people remember when to take their medications, assisting patients who require long-term medication in managing their conditions. In July 2014, it secured $120,000 in investment from Y Combinator and Safa Rashtchy. After three rounds of financing, its total funding has reached $780,000.
By recording and analyzing user behavior, Nightingale tailors its approach to each patient’s needs based on their lifestyle habits, ensuring that medication reminders are no longer fixed at rigid times. Additionally, it enables patients’ family members, guardians, and physicians to monitor medication adherence through a visual analytics dashboard. By providing essential data to private healthcare providers and medical service suppliers, Nightingale plays a more proactive role in disease management, serving as a communication bridge between patients and healthcare professionals.
In terms of application, Nightingale targets the autism treatment market and provides a corresponding solution. It has also developed a safety behavior monitoring toolkit for children with autism, which includes wearable devices, mobile applications, and backend data analytics services. This customizable system allows clinicians and behavioral therapists to determine which data are collected and how they are presented. With Nightingale, even after children leave home, school, or hospital settings, their parents, teachers, and physicians can maintain continuous communication via this monitoring toolkit. They can track the children’s status through real-time data, thereby providing an evidence base for treatment.
46. 20n
Leveraging Synthetic Biology to Manufacture Key Chemicals
Establishment Date: 2013
Headquarters Location: San Francisco
Investment Date: December 2014
Investment Amount: $120,000
Investment Round: Seed Round
By leveraging synthetic biology to manufacture important chemicals, the company secured a $120,000 investment from Y Combinator in 2014. It utilizes machine learning to predict which genes should be used to engineer organisms so that they can naturally produce these valuable chemicals, much like yeast produces alcohol during beer brewing. The company has developed a technology to produce acetaminophen, the active ingredient in the analgesic Tylenol. It has also found a way to reduce the cost of these important chemicals by orders of magnitude.
The metabolic model developed by 20n can predict and compare cellular functions at the molecular level, enabling engineered microbes to produce chemicals with therapeutic utility. 20n has secured contracts worth $1.7 million with the U.S. Defense Advanced Research Projects Agency (DARPA) and a major cosmetics company, and is currently focusing on the production of a broader range of chemicals.
47. Bodyport
Device for Measuring Physiological Data from the Feet
Establishment Date: 2014
Headquarters Location: San Francisco
Investment Date: August 2015
Investment Amount: $120,000
Investment Round: Seed Round
Bodyport, founded in 2014, primarily develops devices that measure physiological data via the feet. In the summer of 2015, it secured a $120,000 investment from Y Combinator (YC). The company is dedicated to developing a novel technology that enables individuals to monitor their health status through a simple step. By leveraging foot-based sensors to capture cardiac signals and employing machine learning algorithms to assess key health indicators, the technology aims to facilitate disease prediction and prevention.
48.unima
Convenient Infectious Disease Diagnosis
Established in: 2015
Headquarters Location: Zapopan, Jalisco, Mexico
Investment Date: May 2016
Investment Amount: $1.3 Million
Investment Round: Seed Round
Unima is a Mexican startup dedicated to bringing diagnostic services to remote areas with limited resources. In May 2016, the company secured $1.3 million in seed funding from 11 investors, including Y Combinator and SP Investment Fund. In these regions, 16% of annual deaths are caused by infectious diseases such as diarrhea, lower respiratory infections, HIV/AIDS, tuberculosis, and malaria.
Unima has developed a rapid, low-cost technology for infectious disease diagnosis and disease surveillance. By simply collecting a small blood sample using specialized diagnostic test strips, antibodies within the paper-based device generate a visual response upon contact with biomarkers in the sample. Images are uploaded to the cloud via a mobile application, where intelligent algorithms analyze them to identify the disease. This enables doctors, nurses, and community health workers to perform point-of-care diagnoses in under 15 minutes without the need for any laboratory equipment.
49.Loop Genomic
High-Throughput Sequencing Technology
Established in: 2015
Headquarters Location: Palo Alto,
Investment Date: November 2015
Investment Amount: $120,000
Investment Round: Seed Round
Loop Genomics’ technology transforms short-read DNA sequencers into high-throughput, long-read, single-molecule DNA sequencing platforms. High-throughput, phased sequencing covering all 16S variable regions is becoming the gold standard for microbiome analysis, capable of generating complete phased maps of viral populations, with broad application prospects in both research and clinical settings. In November 2015, the company secured a $120,000 investment from Y Combinator.
50. Verge Genomics
Analyzing Genetic Data to Develop Personalized Medications
Established in: 2015
Headquarters Location: San Francisco
Investment Time: 2015
Investment Amount: $120,000
Investment Round: Seed Round
Verge Genomics was founded by two Chinese-American PhD students from UCLA. The company leverages machine learning algorithms and comprehensive human genomic data to predict therapeutic efficacy by identifying the combined effects of drugs on multiple genes. Its primary research focus is on brain disorders, and it has established a partnership with a pharmaceutical company. After receiving a $120,000 investment from Y Combinator in 2015, the company subsequently secured $4 million in funding led by IA Ventures.
Neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis are caused by complex interactions among numerous genes. Many drug discovery efforts have failed because researchers targeted only one gene at a time. Verge Genomics has developed a method to map the hundreds of genes involved in disease pathogenesis and can analyze thousands of datasets to predict which drugs will be effective.
51.zPREDICTA
Reconstructing Organ-Specific Human Microenvironments to Predict Drug Development
Established in: 2014
Headquarters Location: Julia Kirshner
Investment Time: 2015
Investment Amount: Not disclosed
Investment Round: Undisclosed
zPREDICTA (formerly known as Ixchel Scientific) is dedicated to eliminating uncertainties in drug development. The company has developed a technology capable of reconstructing organ-specific human microenvironments, leveraging genetic and computational technologies to predict therapeutic efficacy, thereby reducing the risks associated with clinical trials.
The company’s organ-specific products are based on organ reconstruction technology, wherein the microenvironment of each tissue requires ex vivo reconstruction. The reconstructed environments are available in two formats: 3D bioassays (comprehensive systems comprising extracellular matrix, medium additives, and buffers) and a matrix kit (based solely on extracellular matrix). It is worth noting that both of the company’s founders, Julia Kirshner and Mukti Parikh, are women.
52.Benchling
Cloud-Based DNA Research Management Tool
Year Established: 2012
Headquarters Location: San Francisco
Investment Dates: February 2014, October 2016
Investment Amount: $900,000; $7 million (co-investment)
Investment Rounds: Seed Round, Series B
Cory Li and Sajith Wickramasekara founded Benchling in Silicon Valley in 2014: a cloud-based collaborative platform for life sciences R&D. In February 2014, the company secured a $900,000 seed investment from Y Combinator (YC), and its total funding to date has exceeded $12.9 million.
Benchling is a cloud-based DNA research management tool that offers superior solutions for previously fragmented, poorly collaborative, and technologically outdated DNA research. The company leverages software to edit and analyze DNA data, archive sequence files and images, and provide data to biotechnology laboratories and researchers, thereby enabling the tracking of biological data. Additionally, users can freely search shared data, creating an experience akin to a “DNA app store.” Benchling is collaborating with renowned industry laboratories and enterprises, including MIT Labs, Editas Medicine, and other top-20 pharmaceutical laboratories in the United States. The platform currently serves over 40,000 researcher users—a significant increase from just 2,000 users in 2014. Researchers can accurately extract relevant information as needed, with search speeds even faster than performing simple queries on Google.
Benchling’s team is largely composed of alumni from the Massachusetts Institute of Technology (MIT), including engineers from Twitter, Google, and Facebook. Their search expertise spans genetics, neurology, and synthetic biology. By leveraging their specialized knowledge in computer science and biology, they offer distinct advantages over outdated and cumbersome solutions.
53.One Codex
A Genomic Search Engine
Year Established: 2014
Headquarters Location: San Francisco
Investment Date: July 2014
Investment Amount: $120,000
Investment Round: Seed Round
One Codex, founded in March 2014, is a genomic search engine that currently faces challenging financing conditions. Serving as an indexed reference platform compliant with HIPAA regulations, One Codex enables users to search through tens of thousands of bacterial, viral, and fungal datasets in its database. By filtering millions of DNA base pairs per second, the platform helps users rapidly locate the data they need. The company’s medical professionals have sequenced more than 100,000 genomes, generating petabytes of data. Its database contains over 30,000 sets of bacterial, fungal, and viral data, a figure that continues to grow. Clients include public health professionals, researchers, and industry engineers.
The most commonly used tool for genomic searches is an algorithm called “BLAST,” or the “Basic Local Alignment Search Tool,” which can align major biological sequence data. Typically, uploading a file to BLAST takes 2 minutes and 30 seconds. However, uploading data of the same size using One Codex takes less than one-twentieth of a second, meaning its upload speed is 3,000 times faster than that of the BLAST tool.
Nick Greenfield, the founder of One Codex, is a data scientist who also holds a master’s degree in international relations from Stanford University. He describes the company’s services as follows: “If you want to test for tuberculosis, our service enables physicians to collect samples, perform genomic sequencing on those samples, convert biological information into data, and then comprehensively search this data against all known pathogens using every available resource. Ultimately, this allows them to determine whether you have tuberculosis, identify the specific type of tuberculosis, and assess whether it is drug-resistant.” One Codex is also actively expanding into the public health and food safety markets, as U.S. government agencies such as the Food and Drug Administration (FDA) conduct approximately 500 million tests for foodborne pathogens annually—a process that is increasingly shifting toward genomics-based testing.
54. uBiome
Direct-to-Consumer Microbial Genomic Testing Kits
Established: 2012
Headquarters Location: San Francisco
Investment Date: July 2014
Investment Amount: $120,000
Investment Round: Seed Round
uBiome was founded in 2012 and entered the Y Combinator incubator program in 2014. Upon entering the market, uBiome aimed to deepen understanding of the human microbiome and uncover mechanisms that contribute to health. Over the past four years, the company has collected tens of thousands of samples and offered a basic $89 test kit for analyzing individual gut microbes, thereby creating a DNA database of each person’s microbiome.
The company is currently experiencing strong growth, having completed a $22 million Series B financing round in November this year, led by 8VC. The funds will be used to deploy uBiome’s new test kit, SmartGut, which sequences DNA from microbes in your stool. This is a clinical-grade microbiome screening test based on gene sequencing. SmartGut aims to provide comprehensive screening for individuals and their doctors to identify significant microbes that may cause health issues. Currently, DNA sequencing proves to be an excellent method for detection, and uBiome utilizes high-throughput 16S rRNA gene sequencing. The company has established technical collaborations with Stanford University, Harvard University, and the University of California, San Francisco.
55. Diassess
Rapid DNA Sequencing Platform
Established in: 2013
Headquarters Location: Emeryville
Investment Time: December 2014
Investment Amount: $120,000
Investment Round: Seed Round
Genetic testing is often constrained by on-site hardware limitations, a challenge Diassess aims to overcome. With only minimal hardware and a mobile app, DNA testing can be performed in any setting. Users place urine or saliva samples into the sample collector and reactor, then scan the QR code on the device with their smartphone. Test results are delivered via push notification in under 20 minutes, eliminating the hassle of mailing samples.
Auckland Children's Hospital tested this technology and achieved 100% accuracy. Organizations such as the U.S. Defense Advanced Research Projects Agency (DARPA) have expressed support for Diassess. However, due to certain limitations, although Diassess claims to provide health-related information and recommendations, it is primarily used for disease screening, including the prevention, detection, and control of infectious diseases such as influenza and HIV/AIDS. In December 2014, it secured $120,000 in funding from Y Combinator and Data Collective.
56. Cofactor Genomics
Utilizing RNA for Disease Diagnosis
Established in: 2008
Headquarters Location: San Francisco
Investment Date: July 2015
Investment Amount: Undisclosed
Investment Round: Seed Round
Cofactor Genomics is a biotechnology company that leverages RNA sequencing for disease diagnosis. In July 2015, it secured investment from ten institutional investors, including Y Combinator (YC). The company’s core team comprises scientists from the Human Genome Project, who are advancing drug development and clinical diagnostics through RNA testing. Currently, the molecular diagnostics market primarily relies on DNA, proteins, and other chemical markers as diagnostic bases. As a critical component of human information transmission, RNA testing has not received sufficient attention.
Cofactor Genomics combines CAP-CLIA-certified RNA sequencing technology with machine learning algorithms to identify relevant biomarkers that aid in disease diagnosis. Akin to linking fingerprints to individuals, this approach enables the identification of numerous diseases through unique molecular profiles. The company has already signed contracts with pharmaceutical firms to develop RNA-based solutions and promote clinical-grade applications. Due to its pioneering research in RNA, it has also received funding support from the U.S. National Institutes of Health (NIH).
57. Ginko Bioworks
Custom Microbes Company
Established in: 2008
Headquarters: Boston
Investment Period: July 2014, June 2016
Investment Amount: $120,000, $100 million
Investment Rounds: Seed Round, Series C
Ginkgo Bioworks, founded in 2008 and headquartered in Boston, has now become a bona fide unicorn. Since securing seed funding from six investors, including Y Combinator (YC), in 2014, the company has remained a major magnet for capital. This June, it raised another $100 million from six investment firms, including YC, Senator Investment Group, and Viking Global Investors. To date, its total financing has exceeded $150 million.
Ginkgo Bioworks focuses on custom microbes, adopting an engineering approach to biology through highly systematic, large-scale modification trials. By applying rigorous design principles to the genetic engineering of organisms, bioengineers can ultimately develop microbes that produce target products, thereby meeting customer needs. Their research encompasses bacteria for combating antibiotic resistance, the use of microbes to convert carbon dioxide into fuel, and methods to impart a rose fragrance to yeast, primarily by synthesizing scents through genetic engineering or even custom-designed microbes. The company has also expanded into the fields of nutritional products and consumer health goods.
58.Watsi
The World’s First Medical Crowdfunding Non-Profit Organization Dedicated to Developing Countries
Date of Establishment: August 23, 2012
Headquarters Location: San Anselmo, California
Investment Time: July 2013
Investment Amount: $1.2 Million
Investment Round: Seed Round
Watsi, founded in 2012, is a non-profit organization providing crowdfunding-based medical services to patients lacking access to basic healthcare. The organization publishes patients’ medical conditions and needs on its crowdfunding platform to secure donations from supporters. It completed its Series A financing last November, raising a total of $4.7 million.
Watsi’s services have a global reach. By visiting its website, users can view profiles of patients in need, which detail their basic medical conditions and the amount of funding required. The minimum donation is $5. The company aims to establish a direct connection between donors and beneficiaries in developing countries, enabling donors to understand the patients’ actual hardships, including the specific medical services needed and the associated costs. After donating, users can track the status of their contributions in real time via the app. To ensure the accuracy of donations, all patient verification materials are currently validated by Watsi and multiple third-party organizations, including Partners in Health, GiveWell, CNN, ABC, and HBO. As of this November, Watsi had 20,354 donors who raised funds for 9,849 patients across 24 countries.
For high-cost procedures such as cardiac surgery, Watsi reduces treatment costs through in-depth collaborations with healthcare institutions and physicians, according to Chase Adam, founder of Watsi. These partners can leverage their idle capacity to provide medical equipment and services to patients, thereby achieving the platform’s stated goal of “high impact, low cost.” Furthermore, surgical fees in developing countries are lower than those in the United States.
59. Immunity Project
A Non-Profit Organization Focused on HIV Vaccine Development
Establishment Time: 2010
Headquarters: San Francisco
Investment Date: July 2014
Investment Amount: $120,000
Investment Round: Seed Round
Immunity Project is a team composed of scientists and entrepreneurs, based in the San Francisco Bay Area. It was established as a platform to develop revolutionary vaccines and received investment from Y Combinator in July 2014. Immunity Project aims to utilize an algorithm developed by Dr. David Heckerman of Microsoft Research to analyze HIV antibodies found in the rare population of individuals who carry the HIV virus but do not progress to AIDS. By deciphering the life cycle of the HIV virus through this analysis, the project seeks to produce an effective vaccine. However, to date, its product development and clinical trials have not been particularly successful.
The team currently holds 10 granted patents, with several others pending approval, covering vaccine formulations and delivery devices. As designed, the vaccine formulation includes biomarkers for critical vulnerabilities and FDA-approved immunotherapeutic agents. The primary delivery method involves administering a non-refrigerated, inert powder to patients via a nasal inhaler. The Immunity Project is the first to develop a vaccine that contains neither live nor inactivated viruses, thereby providing patients with the safest possible vaccination option. However, the project has consistently faced funding shortages. Although it secured some capital through crowdfunding platforms in 2014, the amount raised remains far short of the $25 million projected by founder Jain.
60. SIRUM
Non-Profit Drug Donation Organization
Establishment Year: 2013
Headquarters Location: Emeryville
Investment Date: December 2014
Investment Amount: $120,000
Investment Round: Seed Round
Sirium, founded in 2009, is an innovative 501(c)(3) non-profit organization that enables healthcare institutions, providers, and pharmacies to easily donate unused medications to recipient clinics. It was initially incubated at Stanford University. In December 2014, it secured $120,000 in investment from Y Combinator.
Sirium has the potential to help reduce over $700 million in unused medication waste annually by enabling closed, secure, and barrier-free peer-to-peer drug redistribution through an online system. Unlike traditional drug redistribution programs, it eliminates many ineffective intermediate steps by directly connecting donating facilities with recipient clinics. Sirium actively identifies potential medication donors and recipients across the country. Good Samaritan laws, which protect qualified donors and recipient organizations involved in pharmaceutical donations, have been established in 40 states across the United States.
61．ReSchedule Med
Medical Education Schedule Adjustment Platform for New Physicians
Established in: 2012
Headquarters: San Francisco
Investment Date: December 2014
Investment Amount: $120,000
Investment Round: Seed Round
ReSchedule Med offers services for rescheduling inpatient programs and secured a $120,000 investment from Y Combinator in December 2014. Schedule adjustment is one of the most troublesome logistical challenges for hospitals and inpatient programs. ReSchedule provides an end-to-end workflow to manage schedule adjustments for medical education programs involving new physicians. Hospital staff often spend hours arranging work schedules. ReSchedule has developed an algorithm that can coordinate work schedules within seconds.
62. stitch
Mobile Healthcare Information Platform for Physicians
Established in: 2015
Headquarters Location: San Francisco
Investment Time: November 2015
Investment Amount: $120,000
Investment Round: Seed Round
Stitch is a platform that facilitates medical information communication for doctors, nurses, social workers, pharmacists, and other healthcare professionals. In November 2015, it secured $120,000 in funding from Y Combinator (YC). Stitch complies with HIPAA standards, leverages AWS and Aptible for technical infrastructure, and integrates with hospitals’ electronic health records (EHRs).
On this platform, physicians can use their mobile phones to communicate, take notes, track tasks, and upload files. It has currently partnered with more than 400 institutions. Regarding the secret to its growth, they attribute it to focusing on nursing homes, rehabilitation facilities, pharmacies, and urgent care centers. Stitch boasts very high user engagement, with users spending an average of eight hours per day on the platform. However, its competitiveness is relatively weak compared to similar companies such as Slack.
63. Elemeno Health
Physician and Nurse Mobile Information Platform
Established in: 2016
Headquarters Location: Not Specified
Investment Date: August 2016
Investment Amount: $120,000
Investment Round: Seed Round
In the United States, medical errors are the third leading cause of death, likely due to inappropriate medical practices. Doctors and nurses may overlook critical checks. ElemenoHealth compiles standardized clinical workflows for hospitals, helping physicians and nurses avoid errors and consistently deliver high-quality, stable medical care. In August 2016, it secured $120,000 in seed funding from Y Combinator.
Elemeno’s pilot project with UCSF has been implemented across 300 hospitals, employing over 200 nurses. It has already saved three lives and reduced costs by $1.1 million. Elemeno’s co-founders gained their insights from frontline hospital experience and now aim to promote this highly accurate approach to every physician and nurse.
64.nurx
New Retail Model for Emergency Prescription Drugs
Establishment Date: 2014
Headquarters: San Francisco
Investment Date: November 2015
Investment Amount: $120,000
Investment Round: Seed Round
Nurx was co-founded by Silicon Valley serial entrepreneur Hans Gangeskar and physician Edvard Engesæth, with a commitment to revolutionizing the retail model for prescription medications. Nurx connects multiple stakeholders, including patients, physicians, pharmacies, insurance companies, and pharmaceutical manufacturers. When patients require prescription medication, physicians on the platform conduct online or telephone consultations and issue appropriate prescriptions. Nurx initially launched pilot programs for oral contraceptives and Truvada, a medication used for HIV prevention, and plans to expand its range of prescription offerings in the future.
Obtaining prescription contraceptives in the United States is challenging, as it requires finding a suitable healthcare provider and engaging in consultations. Nurx positions itself as the most convenient platform for accessing prescription medications. Through Nurx’s web app, users can select the prescribed medications they need. A physician then conducts an online consultation, asking a series of questions typically addressed during in-clinic visits, before issuing a prescription. Within two hours, Nurx delivers the medication directly to the user’s doorstep. The company secured $120,000 in funding from Y Combinator in 2015. Following its Series A financing round this October, its total funding has reached $5.42 million.
65. Perlstein Lab PBC
Automatically Discovering Drugs for Rare Diseases
Established: 2014
Headquarters Location: San Francisco
Investment Date: May 2016
Investment Amount: $120,000
Investment Round: Seed Round
Perlstein Lab PBC can automatically identify drugs for rare diseases, accelerating precision drug discovery for more than 5,000 rare genetic disorders, such as lysosomal storage disorders and mitochondrial diseases. In June 2015, it secured $120,000 in funding from Y Combinator and Slow Ventures. Perlstein Lab employs CRISPR technology to conduct experiments in yeast, nematodes, fruit flies, and zebrafish, aiming to find cures for these conditions.
Subsequently, the Perlstein Lab can sell these drugs directly to patients or license them to other companies for profit. The company has already entered into multiple collaborative agreements with a major pharmaceutical manufacturer and is also working with several medical teams that the pharmaceutical industry considers too small to warrant significant relationship-building efforts.
66. VetPronto
Veterinary Home-Visit Service Platform
Established: 2014
Headquarters Location: San Francisco
Investment Date: December 2014
Investment Amount: $230,000
Investment Round: Seed Round
VetPronto is a house-call veterinary service. Since its founding in San Francisco in 2014, it has expanded its operations to nine regions, including Atlanta, Chicago, and New Orleans. In December 2014, the company raised $230,000 from six investors, including Y Combinator (YC) and Debayan Banerjee. Its total funding to date has reached $1.34 million.
Neither pet owners nor their pets are particularly eager to visit veterinary clinics, as they hope to provide the most attentive care for their pets at home. The company’s website lists the schedules of all veterinarians. Veterinarians undergo a rigorous screening process to ensure that only the most qualified and compassionate professionals join the VetPronto team. Before each appointment, veterinarians thoroughly review the pet’s prior medical records to assess its health status.
The information in this article is sourced from publicly available online materials, including Crunchbase, TechCrunch, and PingWest.